Personal genome testing on physicians improves attitudes on pharmacogenomic approaches.

Kye Hwa Lee,Byung Joo Min,Ju Han Kim,Jinn-Moon Yang

doi:10.1371/journal.pone.0213860

Kye Hwa Lee, Byung Joo Min + Show 2 more

Open Access

https://doi.org/10.1371/journal.pone.0213860

Copy DOI

Abstract

In this era of clinical genomics, the accumulation of knowledge of pharmacogenomics (PGx) is rising dramatically and attempts to utilize it in clinical practice are also increasing. However, this advanced knowledge and information have not yet been sufficiently utilized in the clinical field due to various barriers including physician factors. This study was conducted to evaluate the attitudes of physicians to PGx services by providing them their own genomic data analysis report focusing on PGx. We also tried to evaluate the clinical applicability of whole exome sequencing (WES)-based functional PGx test. In total 88 physicians participated in the study from September 2015 to August 2016. Physicians who agreed to participate in the study were asked to complete a pre-test survey evaluating their knowledge of and attitude toward clinical genomics including PGx. Only those who completed the pre-test survey proceeded to WES and were provided with a personal PGx analysis report in an offline group meeting. Physicians who received these PGx reports were asked to complete a follow-up survey within two weeks. We then analyzed changes in their knowledge and attitude after reviewing their own PGx analysis results through differences in their pre-test and post-test survey responses. In total, 70 physicians (79.5%) completed the pre-test and post-test surveys and attended an off-line seminar to review their personal PGx reports. After physicians reviewed the report, their perception of and attitude towards the PGx domain and genomics significantly changed. Physician’ awareness of the likelihood of occurrence of adverse drug reactions and genetic contribution was also changed significantly. Overall, physicians were very positive about the value and potential of the PGx test but maintained a conservative stance on its actual clinical use. Results revealed that physicians’ perception and attitude to the utility of PGx testing was significantly changed after reviewing their own WES results.

Highlights

With the development of genome analysis technology, next-generation sequencing (NGS) data is increasingly used in the clinical practice [1,2]
The final study group of subjects comprised a total of 70 physicians who completed a pre-test survey, attended an offline meeting, reviewed the results of their personal PGx report, and completed a post-test survey
The physicians’ perceived prevalence of adverse drug reaction (ADR) was increased significantly in the post-test survey compared to pre-test (Table 3) As the introduction of genomic tests in clinical practice has been very rapid over a period of about one year, physicians’ genetic test prescription patterns and getting information resources have been diversified

Summary

Introduction

With the development of genome analysis technology, next-generation sequencing (NGS) data is increasingly used in the clinical practice [1,2]. Physicians’ perception changes on pharmacogenomics before and after their whole exome sequencing. There was no additional external funding received for this study

Objectives

Methods

Results

Discussion

Conclusion